Our Pipeline

At Servier Pharmaceuticals, our core business is focused in oncology where we believe that we have a unique opportunity to redefine how cancer is treated. We are committed to finding solutions that will address today's challenges. We aim to understand the needs of our patients at all points of their journey, while ensuring those who can benefit from our products have access to them. Advancing innovation for patients is at the heart of everything we do. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of research and development dedicated to deliver significant advances in areas of high unmet need that may truly move the needle for our patients. 

Servier’s pipeline includes many oncology assets at varying stages of clinical development.

Hematological Malignancies

Molecule Area Primary Indication Partner Territory Phase

ONCASPAR®

(pegaspargase)

ALL
World
Registered
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia
PARTNER
PARTNER
World
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia
PARTNER
TERRITORY
World
First Line Acute Lymphoblastic Leukemia
World

ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first line acute lymphoblastic leukemia (ALL), ALL and hypersensitivity to native forms of L-asparaginase.

ONCASPAR is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first line acute lymphoblastic leukemia (ALL), ALL and hypersensitivity to native forms of L-asparaginase.

ASPARLAS®

(calaspargase pegol-mknl)

ALL
United States
Registered
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia
PARTNER
PARTNER
United States
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia
PARTNER
TERRITORY
United States
First Line Acute Lymphoblastic Leukemia
United States

ASPARLAS is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years.

ASPARLAS is indicated as a component of a multiagent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years.

PIXUVRI®

(pixantrone)

NHL
World
Registered
PRIMARY INDICATION
Relapsed or Refractory Non-Hodgkin Lymphoma
PARTNER
PARTNER
World
PRIMARY INDICATION
Relapsed or Refractory Non-Hodgkin Lymphoma
PARTNER
TERRITORY
World
Relapsed or Refractory Non-Hodgkin Lymphoma
World

PIXUVRI is indicated for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell Lymphoma. PIXURVI is not registered in the United States.

PIXUVRI is indicated for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell Lymphoma. PIXURVI is not registered in the United States.

TIBSOVO®

(ivosidenib tablets)

IDH1-mutant IC-Ineligible Frontline AML
United States
Registered
PRIMARY INDICATION
First Line Acute Myeloid Leukemia with IDH1 Mutation
PARTNER
PARTNER
United States
PRIMARY INDICATION
First Line Acute Myeloid Leukemia with IDH1 Mutation
PARTNER
TERRITORY
United States
First Line Acute Myeloid Leukemia with IDH1 Mutation
United States

TIBSOVO (ivosidenib tablets) in combination with azacitidine is indicated in the U.S. for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

TIBSOVO (ivosidenib tablets) in combination with azacitidine is indicated in the U.S. for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

TIBSOVO®

(ivosidenib tablets)

R/R IDH1-AML
United States
Registered
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia with a IDH1-mutation
PARTNER
Acquired by Servier from Agios Pharmaceuticals in 2021
PARTNER
United States
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia with a IDH1-mutation
PARTNER
Acquired by Servier from Agios Pharmaceuticals in 2021
TERRITORY
United States
Relapsed or Refractory Acute Myeloid Leukemia with a IDH1-mutation
Acquired by Servier from Agios Pharmaceuticals in 2021
United States

TIBSOVO (ivosidenib tablets) is indicated in the U.S. for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA test in adult patients newly-diagnosed with AML who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy or adult patients with relapsed or refractory AML. 

TIBSOVO (ivosidenib tablets) is indicated in the U.S. for the treatment of acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA test in adult patients newly-diagnosed with AML who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy or adult patients with relapsed or refractory AML. 

TIBSOVO®

(ivosidenib tablets)

IDH1-mutant IC-Ineligible Frontline AML
United States
Registered
PRIMARY INDICATION
First Line Acute Myeloid Leukemia with IDH1 mutation (intensive chemotherapy ineligible)
PARTNER
PARTNER
United States
PRIMARY INDICATION
First Line Acute Myeloid Leukemia with IDH1 mutation (intensive chemotherapy ineligible)
PARTNER
TERRITORY
United States
First Line Acute Myeloid Leukemia with IDH1 mutation (intensive chemotherapy ineligible)
United States

Ivosidenib

IDH1-mutant IC-Eligible Frontline AML
World except for China
Phase 3
PRIMARY INDICATION
First Line Intensive Chemotherapy-Eligible Acute Myeloid Leukemia
PARTNER
PARTNER
World except for China
PRIMARY INDICATION
First Line Intensive Chemotherapy-Eligible Acute Myeloid Leukemia
PARTNER
TERRITORY
World except for China
First Line Intensive Chemotherapy-Eligible Acute Myeloid Leukemia
World except for China

HOVON 150 AML/AMLSG 29-18 is a phase 3, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in IC-eligible patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with excess blasts-2, with an IDH1 or IDH2 mutation

HOVON 150 AML/AMLSG 29-18 is a phase 3, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in IC-eligible patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with excess blasts-2, with an IDH1 or IDH2 mutation

Pegaspargase

ALL
Phase 2
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia
PARTNER
PARTNER
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia
PARTNER
TERRITORY
First Line Acute Lymphoblastic Leukemia

Calaspargase pegol-knl

ALL
World
Phase 2
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia (Patients ≥ 21 years old)
PARTNER
PARTNER
World
PRIMARY INDICATION
First Line Acute Lymphoblastic Leukemia (Patients ≥ 21 years old)
PARTNER
TERRITORY
World
First Line Acute Lymphoblastic Leukemia (Patients ≥ 21 years old)
World

UCART19

R/R ALL
Phase 2
PRIMARY INDICATION
Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia
PARTNER
Allogene
PARTNER
PRIMARY INDICATION
Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia
PARTNER
Allogene
TERRITORY
Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia
Allogene

UCART19

R/R ALL
Phase 2
PRIMARY INDICATION
Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
PARTNER
Allogene
PARTNER
PRIMARY INDICATION
Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
PARTNER
Allogene
TERRITORY
Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
Allogene

Ivosidenib

R/R MDS
World except for China
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Myelodysplastic Syndrome
PARTNER
PARTNER
World except for China
PRIMARY INDICATION
Relapsed or Refractory Myelodysplastic Syndrome
PARTNER
TERRITORY
World except for China
Relapsed or Refractory Myelodysplastic Syndrome
World except for China

BCL-2 Inhibitor

R/R AML + NHL + MM
Novartis/Vernalis
Phase 1
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma
PARTNER
Novartis/Vernalis
PARTNER
PRIMARY INDICATION
Relapsed or Refractory Acute Myeloid Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma
PARTNER
Novartis/Vernalis
TERRITORY
Relapsed or Refractory Acute Myeloid Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma
Novartis/Vernalis

In combination with MCL-1 Inhibitor

In combination with MCL-1 Inhibitor

BCL-2 Inhibitor

Phase 1
PRIMARY INDICATION
PARTNER
PARTNER
PRIMARY INDICATION
PARTNER
TERRITORY

In combination with HMA

In combination with HMA

MCL-1 Inhibitor

AML
Phase 1
PRIMARY INDICATION
Acute Myeloid Leukemia
PARTNER
PARTNER
PRIMARY INDICATION
Acute Myeloid Leukemia
PARTNER
TERRITORY
Acute Myeloid Leukemia

In combination with venetoclax

In combination with venetoclax

MCL-1 Inhibitor

AML
Phase 1
PRIMARY INDICATION
Acute Myeloid Leukemia
PARTNER
PARTNER
PRIMARY INDICATION
Acute Myeloid Leukemia
PARTNER
TERRITORY
Acute Myeloid Leukemia

In combination with azacitidine

In combination with azacitidine

Solid Tumors

Molecule Area Primary Indication Partner Territory Phase

LONSURF®

(trifluridine/tipiracil)

mGC Third Line
World except for North America and Asia
Registered
PRIMARY INDICATION
Third line metastatic Gastric Cancer
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for North America and Asia
PRIMARY INDICATION
Third line metastatic Gastric Cancer
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for North America and Asia
Third line metastatic Gastric Cancer
Taiho Pharmaceutical Co.
World except for North America and Asia

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

LONSURF®

(trifluridine/tipiracil)

mCRC Third Line
Taiho Pharmaceutical Co.
World except for the United States
Registered
PRIMARY INDICATION
Third line metastatic Colorectal Cancer
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for the United States
PRIMARY INDICATION
Third line metastatic Colorectal Cancer
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for the United States
Third line metastatic Colorectal Cancer
Taiho Pharmaceutical Co.
World except for the United States

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

LONSURF (trifluridine and tipiracil) is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

ONIVYDE®

(Liposomal irinotecan)

mPAC post-gemcitabine
Ipsen
World except for the United States and Taiwan
Registered
PRIMARY INDICATION
Post-gemcitabine Metastatic Pancreatic Cancer
PARTNER
Ipsen
PARTNER
World except for the United States and Taiwan
PRIMARY INDICATION
Post-gemcitabine Metastatic Pancreatic Cancer
PARTNER
Ipsen
TERRITORY
World except for the United States and Taiwan
Post-gemcitabine Metastatic Pancreatic Cancer
Ipsen
World except for the United States and Taiwan

ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

*In combination with 5-FU/leucovorin

ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

*In combination with 5-FU/leucovorin

TIBSOVO®

(ivosidenib tablets)

Previously treated IDH1-mutant CCA
United States
Registered
PRIMARY INDICATION
Previously treated IDH1-mutated cholangiocarcinoma
PARTNER
PARTNER
United States
PRIMARY INDICATION
Previously treated IDH1-mutated cholangiocarcinoma
PARTNER
TERRITORY
United States
Previously treated IDH1-mutated cholangiocarcinoma
United States

TIBSOVO (ivosidenib tablets) is approved in the U.S. for previously treated IDH1-mutated cholangiocarcinoma.

TIBSOVO (ivosidenib tablets) is approved in the U.S. for previously treated IDH1-mutated cholangiocarcinoma.

Trifluridine/tipiracil

mCRC First Line
Taiho Pharmaceutical Co.
World except for North America and Asia
Phase 3
PRIMARY INDICATION
First and third line metastatic Colorectal Cancer*
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for North America and Asia
PRIMARY INDICATION
First and third line metastatic Colorectal Cancer*
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for North America and Asia
First and third line metastatic Colorectal Cancer*
Taiho Pharmaceutical Co.
World except for North America and Asia

*In combination with bevacizumab

*In combination with bevacizumab

Trifluridine/tipiracil

mCRC Third Line
Taiho Pharmaceutical Co.
World except for North America and Asia
Phase 3
PRIMARY INDICATION
Third line metastatic colorectal cancer with acquired EGFR resistance
PARTNER
Taiho Pharmaceutical Co.
PARTNER
World except for North America and Asia
PRIMARY INDICATION
Third line metastatic colorectal cancer with acquired EGFR resistance
PARTNER
Taiho Pharmaceutical Co.
TERRITORY
World except for North America and Asia
Third line metastatic colorectal cancer with acquired EGFR resistance
Taiho Pharmaceutical Co.
World except for North America and Asia

​​​​​*In combination with an EGFR inhibitor

​​​​​*In combination with an EGFR inhibitor

Vorasidenib

IDH-mutant Low-Grade Glioma
World
Phase 3
PRIMARY INDICATION
Residual or Recurrent Low-grade Glioma with IDH1/2 mutation
PARTNER
PARTNER
World
PRIMARY INDICATION
Residual or Recurrent Low-grade Glioma with IDH1/2 mutation
PARTNER
TERRITORY
World
Residual or Recurrent Low-grade Glioma with IDH1/2 mutation
World

The INDIGO Study is a Phase 3 clinical trial evaluating the safety and effectiveness of vorasidenib in people with Grade 2 low-grade gliomas with an IDH mutation. 

The INDIGO Study is a Phase 3 clinical trial evaluating the safety and effectiveness of vorasidenib in people with Grade 2 low-grade gliomas with an IDH mutation. 

Anti-MET

MTAP-Deleted NSCLC
World
Phase 2
PRIMARY INDICATION
Non-Small Cell Lung Cancer
PARTNER
PARTNER
World
PRIMARY INDICATION
Non-Small Cell Lung Cancer
PARTNER
TERRITORY
World
Non-Small Cell Lung Cancer
World

Anti-LAG3

Solid Tumors
World
Phase 1
PRIMARY INDICATION
Solid Tumors
PARTNER
PARTNER
World
PRIMARY INDICATION
Solid Tumors
PARTNER
TERRITORY
World
Solid Tumors
World

Anti-NKG2A

Metastatic Gastric or Colorectal Cancers
World
Phase 1
PRIMARY INDICATION
Metastatic Gastric or Colorectal Cancers
PARTNER
PARTNER
World
PRIMARY INDICATION
Metastatic Gastric or Colorectal Cancers
PARTNER
TERRITORY
World
Metastatic Gastric or Colorectal Cancers
World

PD-L1x4-1BB

Solid Tumors
World except for the United States
Phase 1
PRIMARY INDICATION
Solid Tumors
PARTNER
PARTNER
World except for the United States
PRIMARY INDICATION
Solid Tumors
PARTNER
TERRITORY
World except for the United States
Solid Tumors
World except for the United States

MAT2A

ESCC
World
Phase 1
PRIMARY INDICATION
Esophageal Squamous Cell Carcinoma
PARTNER
PARTNER
World
PRIMARY INDICATION
Esophageal Squamous Cell Carcinoma
PARTNER
TERRITORY
World
Esophageal Squamous Cell Carcinoma
World

Anti-CD73

Various Solid Tumors
World
Phase 1
PRIMARY INDICATION
High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
PARTNER
PARTNER
World
PRIMARY INDICATION
High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
PARTNER
TERRITORY
World
High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
World

Anti-PD-1, Anti-TIM3, Irinotecan Combo

Solid Tumors
Symphogen...
World
Phase 1
PRIMARY INDICATION
Second Line Biliary Tract Cancer and Esophageal Squamous Cell Carcinoma
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **
PARTNER
World
PRIMARY INDICATION
Second Line Biliary Tract Cancer and Esophageal Squamous Cell Carcinoma
PARTNER
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **
TERRITORY
World
Second Line Biliary Tract Cancer and Esophageal Squamous Cell Carcinoma
Symphogen is a subsidiary of Servier that serves as the antibody center of excellence. **
World

*License option not yet exercised

*License option not yet exercised

Vorasidenib

IDH-mutant Grade 2-3 Glioma
World
Phase 1
PRIMARY INDICATION
Grade 2-3 Glioma with IDH1/2 mutation
PARTNER
PARTNER
World
PRIMARY INDICATION
Grade 2-3 Glioma with IDH1/2 mutation
PARTNER
TERRITORY
World
Grade 2-3 Glioma with IDH1/2 mutation
World

More from Servier

Research & Development

We invest in innovative research and development through our own development or partnerships to best address the unmet needs of patients.

Learn More

Clinical Trials

We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.

Learn More

About Us

Servier Pharmaceuticals is a privately held pharmaceutical company focused on oncology. Everything we do is to bring the promise of tomorrow to the patients we serve.

Learn More